WO1998043090A3 - In vitro-verfahren zum prognostizieren des mammakarzinoms - Google Patents

In vitro-verfahren zum prognostizieren des mammakarzinoms Download PDF

Info

Publication number
WO1998043090A3
WO1998043090A3 PCT/EP1998/001627 EP9801627W WO9843090A3 WO 1998043090 A3 WO1998043090 A3 WO 1998043090A3 EP 9801627 W EP9801627 W EP 9801627W WO 9843090 A3 WO9843090 A3 WO 9843090A3
Authority
WO
WIPO (PCT)
Prior art keywords
patients
prognosis
carcinoma
breast
condition
Prior art date
Application number
PCT/EP1998/001627
Other languages
English (en)
French (fr)
Other versions
WO1998043090A2 (de
Inventor
Anne Katrin Werenskiold
Original Assignee
Gsf Forschungszentrum Umwelt
Anne Katrin Werenskiold
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gsf Forschungszentrum Umwelt, Anne Katrin Werenskiold filed Critical Gsf Forschungszentrum Umwelt
Priority to CA002284790A priority Critical patent/CA2284790A1/en
Priority to EP98917024A priority patent/EP0970378A2/de
Publication of WO1998043090A2 publication Critical patent/WO1998043090A2/de
Priority to US09/399,646 priority patent/US6399748B1/en
Publication of WO1998043090A3 publication Critical patent/WO1998043090A3/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Für die Prognose und weitere Therapieplanung von Mammakarzinompatienten werden heute in erster Linie der Nodalstatus sowie die Tumorgröße, der histologische Typ, der Differenzierungsgrad und der Rezeptorstatus herangezogen, wobei der Schwerpunkt auf der Beurteilung des axillären Lymphknotenstatus liegt. Patienten mit negativem axillären Lymphknotenstatus werden, da sie eine bessere Prognose haben, in der Regel nicht nachbehandelt; 30 % dieser Patienten entwickeln jedoch Rezidive. Das Verfahren soll es ermöglichen, die Rezidivgefährdung von Patienten festzustellen. Das erfindungsgemäße Verfahren erlaubt durch die qualitative oder quantitative Bestimmung von T1-Protein und/oder T1-mRNA in aus dem Patienten gewonnenem Probenmaterial eine Vorhersage des weiteren Krankheitsverlaufs von Patienten mit Mammakarzinom.
PCT/EP1998/001627 1997-03-21 1998-03-20 In vitro-verfahren zum prognostizieren des mammakarzinoms WO1998043090A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002284790A CA2284790A1 (en) 1997-03-21 1998-03-20 In vitro method for prognosis of the illness evolution of patients with carcinoma of the breast and/or for diagnosing carcinoma of the breast
EP98917024A EP0970378A2 (de) 1997-03-21 1998-03-20 $i(IN VITRO)-VERFAHREN ZUM PROGNOSTIZIEREN DES KRANKHEITSVERLAUFS VON PATIENTEN MIT MAMMAKARZINOM UND/ODER ZUM DIAGNOSTIZIEREN EINES MAMMAKARZINOMS
US09/399,646 US6399748B1 (en) 1997-03-21 1999-09-21 In-vitro method for prognosticating the illness development of patients with carcinoma of the breast and/or for diagnosing carcinoma of the breast

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19711932.8 1997-03-21
DE19711932A DE19711932A1 (de) 1997-03-21 1997-03-21 In vitro-Verfahren zum Prognostizieren des Krankheitsverlaufs von Patienten mit Mammakarzinom und/oder zum Diagnostizieren eines Mammakarzinoms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/399,646 Continuation US6399748B1 (en) 1997-03-21 1999-09-21 In-vitro method for prognosticating the illness development of patients with carcinoma of the breast and/or for diagnosing carcinoma of the breast

Publications (2)

Publication Number Publication Date
WO1998043090A2 WO1998043090A2 (de) 1998-10-01
WO1998043090A3 true WO1998043090A3 (de) 1999-11-11

Family

ID=7824201

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/001627 WO1998043090A2 (de) 1997-03-21 1998-03-20 In vitro-verfahren zum prognostizieren des mammakarzinoms

Country Status (5)

Country Link
US (1) US6399748B1 (de)
EP (1) EP0970378A2 (de)
CA (1) CA2284790A1 (de)
DE (1) DE19711932A1 (de)
WO (1) WO1998043090A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6356782B1 (en) 1998-12-24 2002-03-12 Vivant Medical, Inc. Subcutaneous cavity marking device and method
US6371904B1 (en) 1998-12-24 2002-04-16 Vivant Medical, Inc. Subcutaneous cavity marking device and method
US9669113B1 (en) 1998-12-24 2017-06-06 Devicor Medical Products, Inc. Device and method for safe location and marking of a biopsy cavity
WO2001070817A1 (fr) * 2000-03-21 2001-09-27 Medical & Biological Laboratories Co., Ltd. Anticorps monoclonal et methode et kit d'immunodosage de st2 humaine soluble l'utilisant
HUE039881T2 (hu) 2002-05-09 2019-02-28 Brigham & Womens Hospital Inc 1L1RL-1, mint egy kardiovaszkuláris betegség-marker
DE10337368A1 (de) * 2003-08-08 2005-03-03 Technische Universität Dresden Verfahren und Mittel zur Diagnose und Behandlung von Pankreastumoren
FR2886946B1 (fr) * 2005-06-09 2007-08-10 Biomerieux Sa Procede pour le diagnoctic/pronostic du cancer du sein
ES2351623T3 (es) 2006-04-24 2011-02-08 Critical Care Diagnostics, Inc. Predicción de la mortalidad y detección de una enfermedad grave.
JP5377289B2 (ja) 2006-05-01 2013-12-25 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心血管疾患の診断方法
PT2269063E (pt) 2008-04-18 2013-11-27 Critical Care Diagnostics Inc Predição do risco de eventos cardíacos adversos maiores
US20100083109A1 (en) * 2008-09-29 2010-04-01 Smart Technologies Ulc Method for handling interactions with multiple users of an interactive input system, and interactive input system executing the method
US8810522B2 (en) * 2008-09-29 2014-08-19 Smart Technologies Ulc Method for selecting and manipulating a graphical object in an interactive input system, and interactive input system executing the method
US20100079409A1 (en) * 2008-09-29 2010-04-01 Smart Technologies Ulc Touch panel for an interactive input system, and interactive input system incorporating the touch panel
US8416206B2 (en) * 2009-07-08 2013-04-09 Smart Technologies Ulc Method for manipulating a graphic widget in a three-dimensional environment displayed on a touch panel of an interactive input system
CA2772424A1 (en) * 2009-09-01 2011-03-10 Smart Technologies Ulc Interactive input system with improved signal-to-noise ratio (snr) and image capture method
US8502789B2 (en) * 2010-01-11 2013-08-06 Smart Technologies Ulc Method for handling user input in an interactive input system, and interactive input system executing the method
EP3050901B1 (de) 2010-04-09 2018-08-29 Critical Care Diagnostics, Inc. Lösliche menschliche st-2-antikörper und assays damit
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
A.K. WERENSKIOLD ET AL.: "T1 protein. A novel tumor marker in no-breast carcinoma?", TUMOR BIOLOGY, vol. 18, no. suppl. 2, 19 September 1997 (1997-09-19), Montreux Ch, pages 38 *
A.K. WERENSKIOLD: "Characterization of a secreted glycoprotein of the immunoglobulin superfamily inducible by mitogen and oncogene.", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 204, no. 3, 1992, pages 1041 - 1047 *
BIOLOGICAL ABSTRACTS, vol. 98, Philadelphia, PA, US; abstract no. 107727, XP002076166 *
CHEMICAL ABSTRACTS, vol. 112, no. 17, 23 April 1990, Columbus, Ohio, US; abstract no. 152789, XP002076169 *
CHEMICAL ABSTRACTS, vol. 116, no. 17, 27 April 1992, Columbus, Ohio, US; abstract no. 171919, XP002076168 *
CHEMICAL ABSTRACTS, vol. 118, no. 19, 10 May 1993, Columbus, Ohio, US; abstract no. 188980, XP002076167 *
R. KLEMENZ ET AL.: "Serum- and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoenbryonic antigen.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 86, no. 15, 1989, Bethesda MD USA, pages 5708 - 5712 *
U. ROESSLER ET AL.: "T1, an immunoglobulin superfamily member, is expressed in H-ras-dependent epithelial tumors of mammary cells", ONCOGENE, vol. 8, no. 3, 1993, Bethesda MD USA, pages 609 - 617 *

Also Published As

Publication number Publication date
WO1998043090A2 (de) 1998-10-01
CA2284790A1 (en) 1998-10-01
US6399748B1 (en) 2002-06-04
DE19711932A1 (de) 1998-09-24
EP0970378A2 (de) 2000-01-12

Similar Documents

Publication Publication Date Title
WO1998043090A3 (de) In vitro-verfahren zum prognostizieren des mammakarzinoms
Hammer et al. Immunophenotypic and genotypic analysis in cutaneous lymphoid hyperplasias
Nicholson Use of flow cytometry in the evaluation and diagnosis of primary and secondary immunodeficiency diseases
IT8124138A0 (it) Procedimento e apparecchio per determinare quantitativamente il livello di emoglobina in campioni biologici.
Morrow et al. Does clearing of axillary lymph nodes contribute to accurate staging of breast carcinoma?
RU2218178C2 (ru) Антитела против фосфорилированного vasp (стимулированного вазодилататором фосфопротеина), гибридомные клетки для их получения и их применение
AU6828387A (en) Assay for human breast cancer
DK0991945T4 (da) Fremgangsmåde til identifikation af tumor-antigener med autoantistoffer i serum
DE69731219D1 (de) Beurteilung von cerrixzellen
DE3781745D1 (de) Antikoerper zur verwendung fuer die bestimmung von menschlichem glycoalbumin.
ATE58397T1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
ES2033834T3 (es) Un metodo para determinar alteraciones de la gestion.
IL108811A0 (en) Immunoassay reagents, kits and methods
Hendler et al. Relationship of monoclonal antibody binding to estrogen and progesterone receptor content in breast cancer
Nagar et al. Renal cell (Grawitz) carcinoma: an immunohistochemical study in correlation with nuclear grade, histological pattern and proliferative activity of tumor cells
NZ193126A (en) Method of diagnosis of atherosclerosis and outfit for carrying it out
Pirvu et al. The Texture of Grain Oriented Silicon Steel Strips in Different Phases of Technological Flow
Schwartz Tumor markers
ATE209359T1 (de) Bestimmung von freiem und komplexiertem trypsinogen-2
Tattersall Hormone receptors in tumour cells
Goodson et al. In vivo bromodeoxyuridine (BrdUrd) labeling index as a prognostic marker in human breast cancer
Sinosich et al. Demonstration of antigenic determinants specific for the split products of the third complement factor, C3
Coper THE JUDICIAL INTERPRETATION OF SECTION 92 OF THE AUSTRALIAN CONSTITUTION.
IT8121549A0 (it) Metodo integrato per l'analisi degli anticorpi antistreptolisinici e mezzi adatti allo scopo.
Liston et al. Cell cycling related nuclear antigen expression and detection of hyperplasia in routine endometrial biopsy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2284790

Country of ref document: CA

Ref country code: CA

Ref document number: 2284790

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09399646

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1998917024

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWP Wipo information: published in national office

Ref document number: 1998917024

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998544860

Format of ref document f/p: F

WWW Wipo information: withdrawn in national office

Ref document number: 1998917024

Country of ref document: EP